PubMed Health⌕ Search

Biomedical subjects

J Alom

Publications and source records attributed to J Alom.

10 recordsLinked to original sources
PubMed1992

[Study of neurological and cognitive changes in patients in stage III and initial phases of stage IV of infection by human immunodeficiency virus type 1].

BACKGROUND: To evaluate the prevalence of neurological and cognitive disorders in patients with the human immunodeficiency virus type 1 (HIV-1). METHODS: A transversal prospective study was carried out in 56 patients with HIV-1 and in 18 seronegative subjects by a protocolized neurological and cognitive examination. RESULTS: Twenty-seven patients were intravenous drug users (IVDU) and 29 were male homosexuals. Nineteen were in stage III of HIV-1 infection and 37 were in the initial phases of stage IV. No significant differences were found in the cognitive performance of patients in stage III when the control group was compared with seropositive patients. Significant differences were observed in stage IV in the Rey figure complex tests the B trace test and the number key. Three stage IV patients presented dementia criteria. No significant differences were seen in test performance upon comparing the ex-iVDU seropositive subgroup with the male homosexuals nor in the stage III or stage IV groups. CONCLUSIONS: Cognitive performance of stage III patients did not significantly differ from that of the seronegative control group; a global diminution in cognitive performance was observed in the stage IV group and there were no differences in the cognitive state between the two risk groups analyzed.

Acquired Immunodeficiency Syndrome↗
PubMed1990

Subacute cerebellar syndrome as the first manifestation of AIDS dementia complex.

A patient presented with a subacute cerebellar syndrome in absence of cognitive impairment or other symptoms. He became demented several months after the onset of the disease. Necropsy demonstrated the typical features of the AIDS dementia complex and severe loss of Purkinje cells of the cerebellum. Patients with subacute cerebellar dysfunction should be evaluated for the presence of human immunodeficiency virus infection.

AIDS Dementia Complex↗
PubMed1990

Cerebrospinal fluid neuropeptide Y in Alzheimer's disease.

The cerebrospinal fluid neuropeptide Y level was measured by radioimmunoassay in 20 patients with probable Alzheimer's disease and in 19 controls. The mean level was lower in patients (69.5 +/- 36.7 pg/ml) than in controls (103 +/- 21.8 pg/ml; p less than 0.001). Patients with a disease duration of greater than 2 years had cerebrospinal fluid neuropeptide Y levels lower than those with shorter disease duration (p less than 0.02). These results suggest that neuropeptide Y containing cells may be involved in Alzheimer's disease. No correlation was found between neuropeptide Y levels and degree of cognitive impairment or age at disease onset.

Aged↗
PubMed1990

[Lumbosacral spinal cord infarction. Data from magnetic resonance imaging].

A 77-year old woman and a 61-year old man with lumbosacral spinal cord ischaemic lesions and paraplegia presented with dissociated or partial forms of the lumbar enlargement artery (Adamkiewicz's artery) syndrom. Magnetic resonance imaging (MRI) was performed in both patient with an 0.15 Tesla resistive magnet. A hypersignal on T2-weighted images was present in both cases, which corresponded to the infarction affecting the lumbosacral part of the cord. MRI provided accurate delineation of the lesions and clinicoradiological correlations in both patients. The hypersignal occupied the lumbar cord in case 1 and the conus medullaris in case 2. The clinical signs and location of the lesions seemed to be determined by the different patterns of lumbosacral arterial supply. Since such images could be confused with tumoral images, surgical exploration was carried out in both patients; it failed to demonstrate any tumour or cyst and only showed a pale cord. Surgical cord biopsy in case 2 demonstrated ischaemic tissue. We conclude that ischaemia of the spinal cord can be demonstrated by MRI, but owing to the low specificity of this imaging method aedema cannot be distinguished from necrosis, gliosis or demyelination.

Aged↗
PubMed1989

[AIDS dementia complex as the 1st manifestation of the acquired immunodeficiency syndrome].

In a prospective follow-up period from September 1987 to August 1988, the AIDS dementia complex (ADC) was the presenting clinical feature in six of 102 patients in whom AIDS was diagnosed in the Hospital Clínic i Provincial from Barcelona. The clinical picture was characterized by subcortical type deterioration and motor disturbances. Cerebrospinal fluid investigation and imaging techniques excluded other types of neurological involvement, and the diagnosis was confirmed at autopsy in two patients. The present study suggested that: 1) the ADC may be the presenting feature of AIDS in patients with unknown seropositive status; 2) in our area, ADC represents one of the most common causes of dementia in young patients, and 3) although a specific marker permitting a definitive clinical diagnosis is not available, at the time of diagnosis all patients had a severe degree of cellular immunosuppression induced by type 1 human immunodeficiency virus.

AIDS Dementia Complex↗
PubMed1989

[AIDS dementia complex].

The AIDS dementia complex (ADC) is the SNC complaint that appears most frequently in AIDS patients. ADC is characterized by a subacute onset of dementia accompanied by motor disturbance and changes in behaviour and is considered to be directly caused by HIV-1. Very frequent in advanced stages of AIDS, it can also be the way in which the illness appears. In 90% of the necropsies of these patients a diffuse demyelination of the white substance is observed with multinucleate cells appearing in 40% of the cases. Up to now, the factors triggering this disease are not well understood, nevertheless, the immunosuppression present in these individuals could act as a factor favouring the appearance of ADC. A specific marker does not exist and, therefore, the complementary studies can only help to eliminate other causes of neurological complaints. Successful tests of treatment with zidovudine have been made, although it would be necessary to carry out studies with a larger number of patients to be able to evaluate its long-term efficacity.

AIDS Dementia Complex↗
PubMed1986

5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial.

One hundred and twenty-four migraineurs were treated randomly with 5-hydroxytryptophan (5-HTP) or with methysergide (M). The two groups were homogeneous without significant statistical differences with respect to age, sex, pill use, type of migraine and frequency of attacks before entry. A significant improvement was observed in 75% of the patients treated with M and in 71% of the cases treated with 5-HTP. The most beneficial effect of 5-HTP appears to be felt with regard to the intensity and duration rather than the frequency of the attacks. Side effects were more frequent in the M group than in the 5-HTP group. These results suggest that 5-HTP could be a treatment of choice in the prophylaxis of migraine.

5-Hydroxytryptophan↗